Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to	STATEMENT OF (
Section 16. Form 4 or Form 5	
obligations may continue. See	

CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RINGO WILLIAM R											g Symbol CES INC			tionship of Reportin all applicable) Director		10% Owr		vner	
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD					06/	3. Date of Earliest Transaction (Month/Day/Year) 06/03/2015 4. If Amendment, Date of Original Filed (Month/Day/Year)									Officer (give title below)		Other (below) P Filing (Check A)		
(Street) RICHMOND CA 94804				-									ine) X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	ate) ((Zip)																
		Tab	le I - N	Non-Deriv	/ative	e Sec	uriti	ies A	cquire	d, D	isposed c	f, or B	enefici	ally	Owned	ł			
Date			2. Transacti Date (Month/Day		Execu Year) if any		. Deemed ecution Date, iny onth/Day/Year)		ction Instr.				nd 5) Secur Bene Owne		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 06/03/20				015	15			M		2,200	A	\$6.0	5 3		,000		D		
Common Stock 06/03/202				015	15		S ⁽¹⁾		2,200	D	\$12.43	83(2)	800			D			
		Т	able I								posed of, , converti				wned				
Derivative Conversion		3. Transaction Date (Month/Day/Year)	Execut if any			action Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Own Solly Dir Or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amour or Number of Shares	er					
Stock Option (Right to	\$6.05	06/03/2015			M			2,200	(3))	04/15/2020	Commor Stock	2,200	0	\$0	31,000)	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2014, as amended.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.36 to \$12.53, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- $3. \ All$ shares underlying this option are vested and immediately exercisable

Remarks:

/s/ Florence Tam, Attorney-in-06/03/2015 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.